News

Prevention of the development of cardiovascular diseases is one of the greatest challenges of health care. Controlling risk factors is key to the prevention of the development of these diseases. Various risk factors often occur together, e.g. more than half of all people with high blood pressure also have high cholesterol. When these two risk factors occur together, their impact on disease progression is not summed but multiplied. Failing to control high blood pressure and cholesterol in practice is worrying.

The symposium was attended by around 130 experts from 5 European countries.

Along with the congress of the European Society of Atherosclerosis on 25 April in Prague Krka's international symposium entitled The Power of Synergy, attended by over 130 experts from 5 European countries discussed the challenges and advantages of concurrent treatment of high blood pressure and cholesterol.

At Krka we are aware of the significance of prevention of cardiovascular events and the need for new treatment methods for patients with several risk factors. Our newest solution is fixed-dose combinations of medicines that enable concurrent treatment of high blood pressure and cholesterol with only one tablet a day. Such is for example a fixed-dose combination of rosuvastatin and amlodipine. This year we will be the first in Europe to launch a fixed-dose combination of rosuvastatin and valsartan. These medicinal products enable adjustment of treatment to patients in a way that they help improve patient compliance and prevent many occurrences of cardiovascular events.

Together with experts we spread awareness on the significance of preventing cardiovascular diseases and once again push the limits of treatment.